Core Viewpoint - The Chinese vaccine industry is transitioning from scale expansion to value creation, driven by national immunization strategies and WHO vaccine prioritization policies, with local companies leveraging technological innovation to enhance multi-valent vaccines and lifecycle protection strategies [1] Group 1: Product Development and Innovation - CanSino Biologics' 13-valent pneumonia vaccine PCV13i has been approved for market launch, representing a significant step in the globalization of domestic vaccines [2] - The core value of PCV13i is based on three pillars: technological breakthroughs, clinical validation, and application optimization [2] - The vaccine employs a unique dual carrier technology using a non-toxic mutant of diphtheria toxin (CRM197) and tetanus toxin (TT), enhancing immunogenicity and reducing interference with other vaccines [3] Group 2: Clinical Data and Efficacy - Clinical data shows that PCV13i significantly outperforms control groups in inducing high levels of specific antibodies against key serotypes that are prevalent in China, confirming its regional adaptability [4] - The safety profile of PCV13i is comparable to that of control vaccines, with adverse reactions primarily being mild, facilitating its commercial application [4] Group 3: Market Demand and Commercialization - The urgency for pneumonia vaccines is underscored by the high mortality rates associated with pneumonia in children under five, particularly in China, where vaccination rates are below 18% [6][8] - The global market for pneumonia vaccines is robust, with the 13-valent pneumonia vaccine consistently ranking among the top-selling vaccines, indicating significant market potential [9] Group 4: Strategic Market Positioning - PCV13i is positioned to leverage existing distribution networks and cold chain logistics established by CanSino's previous vaccine, enhancing market penetration efficiency [10] - The vaccine's production process meets EU GMP standards and is suitable for halal certification, providing a competitive edge in Southeast Asian markets [10] Group 5: Long-term Value Creation - CanSino's vaccine matrix, including products for polio and DTP, is establishing a comprehensive defense against bacterial diseases in children, aligning with international quality standards [11] - The launch of PCV13i is expected to catalyze short-term performance while the ongoing innovation in the product matrix builds long-term value, suggesting potential for re-evaluation in market valuation [12]

4月20日晚间，百克生物(688276)发布了其2024年年报。财报显示，报告期内，公司实现的营业收入约为12.29亿元，同比下降32.64%;对应实现的归属净利润 约为2.32亿元，同比下降53.67%。 对此，百克生物表示，主要系本报告期带状疱疹疫苗销量减少所致。这一业绩也预示着国内"带疱一哥"在其核心品种商业化的第二年便遭遇滑铁卢。然而， 受到百克生物此次年报业绩表现打击最大的似乎并非百克本身，而是尚未实现产品收入且核心带疱疫苗即将上市的绿竹生物-B(02480)。 陷入流动性陷阱，亟待被"拯救" 今年5月2日，绿竹生物股价在结束了长达1个半月的横盘后，出现大幅收跌9.09%，引发了场内持筹者的大幅抛售，当日成交量达到180.36万股，打破了绿竹 生物股票2024年以来的单日成交量新高。 智通财经APP观察到，2024年以来，绿竹生物股票流动性出现了断崖式下跌，截至目前的17个月内，单月成交量不超过20万股的月份有10个，单月成交量最 低的月份为今年1月，整月成交量仅22800股。从成交量来看，绿竹生物显然已滑落至被市场遗忘的边缘，亟待被"拯救"。 对于绿竹生物而言，此前最合适的捷径自然是"入通"，但" ...